Sobi, an international biopharmaceutical company dedicated to rare diseases, announced today that Kevin Springman has joined the company as the Vice President, Franchise Head of Synagis® (palivizumab) in North America.
Springman has over 22 years of pharmaceutical and biotech experience spanning sales, marketing, market access, strategic project management and patient services. He spent two decades at AstraZeneca, most recently serving as Franchise Head of Infectious Disease. He previously served as a Senior Director of Strategic Products, and prior to that advanced through multiple sales, marketing and other commercial positions. Kevin received his bachelor’s degree from St. Joseph’s University and completed a post-graduate program at Fork Union Military Academy.
“With the completion of Sobi’s acquisition of rights to Synagis in the U.S., Sobi in North America was pleased to welcome the Synagis sales and marketing team, including Kevin as the franchise head, to our North American team. This acquisition nearly tripled the size of our organization, establishing a critical scale to drive sustainable growth in the U.S. Additionally, Kevin’s deep understanding of Synagis specifically and of strategic sales and marketing generally will make him a valuable addition to our leadership team,” said Rami Levin, President of Sobi in North America.
“I have had the privilege of helping deliver Synagis not only to physicians and hospitals but also the patients that need it for several years, and I am grateful to now have the opportunity to help Sobi continue this important work,” said Springman.
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).